These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 24720402

  • 1. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, Bixalomer Study Group.
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [Abstract] [Full Text] [Related]

  • 2. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [Abstract] [Full Text] [Related]

  • 3. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
    Gen S, Sasaki T, Saito K, Nobe K, Nodaira Y, Ikeda N.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
    Akizawa T, Kameoka C, Kaneko Y, Kawasaki S, Bixalomer Study Group.
    Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
    [Abstract] [Full Text] [Related]

  • 5. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
    Ito K, Takeshima A, Shishido K, Wakasa M, Kumata C, Matsuzaka K, Nakajima Y, Ogata H.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
    [Abstract] [Full Text] [Related]

  • 6. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K, Ikawa T, Yokoi S, Yokouchi S, Kato K, Ueno M, Takahashi J.
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H.
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [Abstract] [Full Text] [Related]

  • 8. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K, Kakuta H.
    Eur J Pharmacol; 2015 Nov 05; 766():129-34. PubMed ID: 26452517
    [Abstract] [Full Text] [Related]

  • 9. Clinical experiences of bixalomer usage at our hospital.
    Shima H, Makino R, Hata K, Ban A, Funao K, Sugita S, Furumitsu Y, Inoue K, Yoshimoto M, Okamura M.
    Ther Apher Dial; 2014 Jun 05; 18 Suppl 2():13-8. PubMed ID: 24975890
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.
    Hatakeyama S, Murasawa H, Narita T, Oikawa M, Fujita N, Iwamura H, Mikami J, Kojima Y, Sato T, Fukushi K, Ishibashi Y, Hashimoto Y, Koie T, Saitoh H, Funyu T, Ohyama C.
    BMC Nephrol; 2013 Oct 12; 14():222. PubMed ID: 24119202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, Kono T, Uchino J, Masaki K, Date T, Shigematsu T, Research Group for Future Hemodialysis.
    Ther Apher Dial; 2008 Apr 12; 12(2):126-32. PubMed ID: 18387160
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis.
    Akizawa T, Tsukada J, Kameoka C, Kuroishi K, Yamaguchi Y.
    Ther Apher Dial; 2017 Apr 12; 21(2):173-179. PubMed ID: 28194884
    [Abstract] [Full Text] [Related]

  • 17. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB, Shepler BM.
    Pharmacotherapy; 2009 May 12; 29(5):554-61. PubMed ID: 19397463
    [Abstract] [Full Text] [Related]

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep 12; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
    Senatore M, Coppolino G, Papalia T, Greco R, Lofaro D, Bonofiglio R.
    Eur Rev Med Pharmacol Sci; 2011 Nov 12; 15(11):1352-4. PubMed ID: 22195373
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.